These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 2699034)
1. Development of immunotherapeutic strategies for the treatment of malignant neoplasia. Talmadge JE Pathol Immunopathol Res; 1989; 8(5-6):250-75. PubMed ID: 2699034 [TBL] [Abstract][Full Text] [Related]
2. Immunotherapeutic strategies for neoplasia. Talmadge JE Dev Biol Stand; 1992; 77():17-28. PubMed ID: 1426659 [No Abstract] [Full Text] [Related]
3. Development of immunotherapeutic strategies for the treatment of malignant neoplasms. Talmadge JE Biotherapy; 1992; 4(3):215-36. PubMed ID: 1599805 [TBL] [Abstract][Full Text] [Related]
4. Biological response modifiers (BRM), chemotherapy, and activated cytotoxic leukocyte subsets: strategies for rational design of apheresis-based cancer immunotherapies. Stevenson HC; Klein HG Prog Clin Biol Res; 1990; 337():559-65. PubMed ID: 2353018 [No Abstract] [Full Text] [Related]
6. Cancer therapy with combinations of biological response modifiers and cytotoxics: an update. Borden EC; Creekmore SP Cancer Cells; 1990 Jul; 2(7):217-20. PubMed ID: 2204387 [TBL] [Abstract][Full Text] [Related]
7. Combination of BRMs with chemotherapy. Tursz T Am J Med; 1995 Dec; 99(6A):56S-58S. PubMed ID: 8585538 [No Abstract] [Full Text] [Related]
9. [Immunomodulation in cancer. What do we do and where do we go?]. Rodríguez Orozco AR; Serriteño NM Rev Alerg Mex; 2005; 52(2):96-101. PubMed ID: 16158783 [TBL] [Abstract][Full Text] [Related]
10. Systemic treatment of malignant melanoma. Mota A; Deisseroth A Clin Plast Surg; 2000 Jul; 27(3):463-74, x. PubMed ID: 10941566 [TBL] [Abstract][Full Text] [Related]
11. Role of biological response modifiers in immunochemotherapy of solid tumors and retroviral-induced leukemia. Fuggetta MP; D'Onofrio C; Bonmassar E Ann Ist Super Sanita; 1990; 26(3-4):385-95. PubMed ID: 1708953 [TBL] [Abstract][Full Text] [Related]
12. The Latest Cancer Agents and Their Complications. Dubbs SB Emerg Med Clin North Am; 2018 Aug; 36(3):485-492. PubMed ID: 30037436 [TBL] [Abstract][Full Text] [Related]
13. [Combination of chemotherapy and immunotherapy in man--review]. Ohnuma T Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1428-36. PubMed ID: 1697154 [TBL] [Abstract][Full Text] [Related]
14. Biological response modifiers: preclinical and clinical results. Talmadge JE; Clark J Cancer Chemother Biol Response Modif; 1987; 9():454-72. PubMed ID: 3079413 [No Abstract] [Full Text] [Related]
15. Biological response modifiers: current use and future prospects in cancer therapy. Bisht M; Bist SS; Dhasmana DC Indian J Cancer; 2010; 47(4):443-51. PubMed ID: 21131760 [TBL] [Abstract][Full Text] [Related]
16. [Tumoricidal biological response modifiers (BRM)]. Niitsu Y; Kohgo Y; Watanabe N Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1407-13. PubMed ID: 1697152 [TBL] [Abstract][Full Text] [Related]
18. Biological Response Modifier in Cancer Immunotherapy. Liu R; Luo F; Liu X; Wang L; Yang J; Deng Y; Huang E; Qian J; Lu Z; Jiang X; Zhang D; Chu Y Adv Exp Med Biol; 2016; 909():69-138. PubMed ID: 27240457 [TBL] [Abstract][Full Text] [Related]
19. MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside. Wittig B; Schmidt M; Scheithauer W; Schmoll HJ Crit Rev Oncol Hematol; 2015 Apr; 94(1):31-44. PubMed ID: 25577571 [TBL] [Abstract][Full Text] [Related]
20. Development of proteasome inhibitors in oncology and autoimmune diseases. Bennett MK; Kirk CJ Curr Opin Drug Discov Devel; 2008 Sep; 11(5):616-25. PubMed ID: 18729013 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]